Get the Stockscreener App
89.96
0.64%
-0.58
Glaukos Corporation stock is traded at $89.96, with a volume of 511.97K.
It is down -0.64% in the last 24 hours and down -3.84% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$90.54
Open:
$90.75
24h Volume:
511.97K
Relative Volume:
0.48
Market Cap:
$5.01B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-30.39
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
+2.68%
1M Performance:
-3.84%
6M Performance:
-36.54%
1Y Performance:
-16.41%
1-Day Range:
$89.55
$91.83
1-Week Range:
$84.26
$92.27
52-Week Range:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
89.96 | 5.01B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos (GKOS) Analyst Rating Update: Price Target Revised Downw - GuruFocus
Glaukos projects 2025 sales in the $475M-$485M range with strong iDose ramp - MSN
Decoding Glaukos Corp (GKOS): A Strategic SWOT Insight - GuruFocus
Stephens cuts Glaukos stock price target to $115 from $140 By Investing.com - Investing.com South Africa
What 11 Analyst Ratings Have To Say About Glaukos - Benzinga
GKOS: Stephens & Co. Lowers Price Target for Glaukos to $115 | G - GuruFocus
Stephens cuts Glaukos stock price target to $115 from $140 - Investing.com
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript - MSN
Glaukos (GKOS) Price Target Reduced by Stephens Following Earnin - GuruFocus
Glaukos (GKOS) Price Target Reduced by Stephens Following Earnings Report | GKOS Stock News - GuruFocus
Glaukos First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline - MSN
How To Trade (GKOS) - news.stocktradersdaily.com
Glaukos Corp. Reports Record Revenue and Growth - TipRanks
Glaukos (GKOS) Sees Price Target Reduction by Stifel Analyst | G - GuruFocus
Needham cuts Glaukos stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
JPMorgan cuts Glaukos stock target to $100 from $160 By Investing.com - Investing.com Nigeria
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Needham cuts Glaukos stock price target to $115, maintains Buy - Investing.com Australia
Glaukos (GKOS) Price Target Revised Down to $135 by Truist Securities | GKOS Stock News - GuruFocus
Needham Maintains Buy Rating for Glaukos (GKOS) with Adjusted Pr - GuruFocus
GKOS Stock Downgraded by Wells Fargo | GKOS Stock News - GuruFocus
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Wells downgrades Glaukos with iDose growth priced in - TipRanks
Truist Adjusts Price Target on Glaukos Corp to $135 From $140, Maintains Buy Rating - marketscreener.com
Glaukos stock hits 52-week low at $77.69 amid market challenges - Investing.com India
Glaukos (GKOS) Target Price Cut by Needham Amidst Revenue Beats - GuruFocus
Glaukos (GKOS) Target Price Cut by Needham Amidst Revenue Beats | GKOS Stock News - GuruFocus
Glaukos (GKOS) Receives Adjusted Price Target but Maintains Buy Rating | GKOS Stock News - GuruFocus
Glaukos (GKOS) Downgraded by Wells Fargo with Reduced Price Targ - GuruFocus
S&P 500 Futures Rise in Premarket Trading; McCormick Vtg, Glaukos Lag - Barron's
JPMorgan cuts Glaukos stock target to $100 from $160 - Investing.com
GLAUKOS Corp SEC 10-Q Report - TradingView
Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... - Yahoo Finance
Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sal - GuruFocus
Glaukos Corp. Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Glaukos Corp beats Q1 2025 EPS forecast, stock falls - Investing.com Nigeria
Glaukos: Q1 Earnings Snapshot - MySA
Glaukos Corp earnings beat by $0.13, revenue topped estimates - Investing.com Canada
Why Glaukos Shares Are Sliding Despite Strong Q1 - TipRanks
Glaukos shares fall as Q1 earnings beat overshadowed by outlook - Investing.com Nigeria
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):